Furthermore, PAI-1 is associated with common comorbidities of COPD, such as atherosclerosis and metabolic syndrome, and PAI-1 inhibition is considered a promising therapeutic approach in clinical practice. Here, SERPINE1 is linked to metabolic syndrome.